

DAFTAR PUSTAKA

- 1 Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, dan Loscalzo J. *Harrison's Principles of Internal Medicine*. Edisi 19. New York NY, McGraw Hill Education. 2015.
- 2 Rees F, Doherty M, Grainge MJ, Davenport G, Lanyon P, dan Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. *Ann Rheum Dis*. 2016;75(1):136–41.
- 3 Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. *J Clin Pathol*. 2003;56:481–90.
- 4 Rees F, Doherty M, Grainge MJ, Lanyon P, dan Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. *Rheumatology*. 2017; 56(11): 1945–61.
- 5 Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, dan Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. *Arthritis Care Res*. 2012;64(2):159–68.
- 6 Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. *Infodatin: Situasi Lupus di Indonesia*. 2017.
- 7 Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, dan Cooper GS. Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. *Semin Arthritis Rheum*. 2010; 39(4): 257.
- 8 Thumboo J, Uramoto K, O'Fallon WM, Fong KY, Boey ML, Feng PH, *et al*. A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, Minnesota, and Chinese in Singapore, from 1980 to 1992. *Arthritis Rheum*. 2001;45:494–500.
- 9 Chen S, Gu YY, Bao CD, dan Chen SL. An 18-year follow-up study of a lupus cohort in Shanghai. *APLAR J Rheumatol* 2006;9: 327–30.
- 10 Sumariyono S, Kalim H, Setyohadi B, Hidayat R, Najirman N, Hamijoyo L, *et al*. Rekomendasi Perhimpunan Rheumatologi Indonesia Untuk Diagnosis dan

Pengelolaan Lupus Eritematosus Sistemik. Jakarta: Perhimpunan Rheumatologi Indonesia. 2019.

- 11 Bertsias GK, Cervera R, dan Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. EULAR textbook on rheumatic diseases, Geneva, Switzerland: European League Against Rheumatism. 2012;2012:476—505.
- 12 Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principle of Internal Medicine. Edisi 18. New York NY, McGraw Hill Education. 2012.
- 13 Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy S, dan Sargent JS. Kelley's Textbook of Rheumatology. Edisi 8. Philadelphia, Elsevier. 2008.
- 14 Uribe AG, Vilá LM, Mcgwin Jr G, Sanchez ML, Reveille JD, dan Alarcón GS. The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K Are Adequate Instruments to Measure Disease Activity in Systemic Lupus Erythematosus. *J Rheumatol*. 2004;31:1934—40.
- 15 Fu SM, Dai C, Zhao Z, dan Gaskin F. Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus. *F1000Research*. 2015; 4(F1000 Faculty Rev):939.
- 16 Fabrizio C, Fulvia C, Carlo P, Laura M, Elisa M, Francesca M, *et al*. Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. *Mediat Inflamm*. 2015;2015(328078): 1—6.
- 17 Foster MH, Cizman B, dan Madaio MP. Nephritogenic es in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. *Lab Invest*. 1993; 69(5):494—507.
- 18 Pascual V, Farkas L, dan Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. *Curr Opin Immunol*. 2006;18(6):676—82.
- 19 Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, dan Kallenberg CGM. Measurement of increases in anti double-strandedDNA antibody levels as a

- predictor of disease exacerbation in systemic lupus erythematosus. *Arthritis & Rheumatism*. 1990;33(5):634–43.
- 20 Narayanan K, Marwaha V, Shanmuganandan K, dan Shankar S. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies. *MJAFLI*. 2010; 66 : 102–7
- 21 Pradesta R, Liana P, dan Haryadi K. Hubungan Hasil Laboratorium Pasien Lupus Eritematosus Sistemik dengan Skor SLEDAI di RSUP Dr Mohammad Hoesin Palembang. *Indones Biomed J*. 2018; 4(3): 112–20.
- 22 Gladman DD, Urowitz MB, dan Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus. *Am J Med*. 1979; 66: 210–5
- 23 Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. *Ann Rheum Dis*. 1994;53:675–80.
- 24 Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. *Curr Opin Rheumatol*. 2017; 29:1-7.
- 25 Flower C, Hennis AJ, Hambleton IR, Nicholson GD, dan Liang MH. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. *Arthritis Care Res*. 2012;64:1151–8.
- 26 Nightingale AL, Farmer RD, de Vries CS. Systemic lupus erythematosus prevalence in the UK: methodological issues when using the General Practice Research Database to estimate frequency of chronic relapsing remitting disease. *Pharmacoepidemiol Drug Saf*. 2007;16:144–51
- 27 Pisetsky DS. Systemic lupus erythematosus. A. Epidemiology, pathology and pathogenesis. In: Klippel JH, ed. *Primer on the rheumatic diseases*, 11th ed. Georgia, USA: Arthritis Foundation, 1997:246–51
- 28 Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, *et al*. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. *PLoS Genetics*. 2011; 7(3).

- 29 Formiga F, Moga I, Pac M, Mitjavila F, Rivera A, dan Pujol R. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. *Lupus*. 1999;8:462–5.
- 30 French MA, Hughes P. Systemic lupus erythematosus and Klinefelter's syndrome. *Ann Rheum Dis*. 1983;42:471–3.
- 31 Cohen-Solal JF, Jeganathan V, Hill L, Kawabata D, Pinto-Rodriguez D, Grimaldi C, *et al*. Hormonal regulation of B-cell function and systemic lupus erythematosus. *Lupus*. 2008;17:528–32
- 32 Sequeira JF, Keser G, Greenstein B, Wheeler MJ, Duarte PC, Khamashta MA, *et al*. Systemic lupus erythematosus: sex hormones in male patients. *Lupus*. 1993;2:315–7
- 33 Smith-Bouvier DL, Divekar AA, Sasidhar M, Du S, Tiwari-Woodruff SK, King JK, *et al*. A role for sex chromosome complement in the female bias in autoimmune disease. *J Exp Med*. 2008;205:1099–108
- 34 Rahman A, Isenberg DA. Systemic lupus erythematosus. *N Engl J Med* 2008;358:929–39
- 35 Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. *Medicine (Baltimore)*. 2008;87:311–8
- 36 Aslanidis S, Pырpasopoulou A, Kontotasios K, Doumas S, dan Zamboulis C. Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway? *Eur. J Intern. Med*. 2008;19:314–8
- 37 McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, dan James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. *Nat Med*. 2005;11:85–9
- 38 Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. *Best. Pract. Res. Clin Rheumatol*. 2008;22:883–96
- 39 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1997;40:1725.
- 40 Hahn BH. Antibodies to DNA. *N Engl J Med*. 1998. 338 : 1359–68.

- 41 Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, dan James JA. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med* .2003. 349:1526—33.
- 42 Rouquette AM, Desgruelles C. Detection of antibodies to dsDNA: an overview of laboratory assays. *Lupus*. 2006. 15:403—7.
- 43 Sudigdo S. *Dasar-dasar Metodologi Penelitian Klinis*. Edisi 4. Jakarta. Sagung Seto. 2011.
- 44 Dahlan MS. *Statistik untuk Kedokteran dan Kesehatan*. Edisi 6. Epidemiologi Indonesia. 2014.
- 45 Yunaz N. Hubungan Aktivitas Penyakit dengan Profil Lipid pada Penderita Lupus Eritematosus Sistemik (Skripsi). Universitas Andalas; 2015.
- 46 Marpaung B, Patrick J. The relationship between increased levels of Anti-dsDNA with clinical manifestation in patients with SLE in Haji Adam Malik General Hospital Medan. *IOP Conf. Ser.: Earth Environ. Sci*. 2018; 125(1):1—5.
- 47 Ghassani NG, Hadi S, Hamijoyo L. Early Detection of Suspected Systemic Lupus Erythematosus in Community-Dwellings in West Java Indonesia. *AMJ*. 2017;4(3):358—62.
- 48 Khanna S, Pal H, Pandey RM, dan Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. *Rheumatology* 2004;43:1536—40.
- 49 Tyden H, Lood C, Gullstrand B, Jonsen A, Ivars F, dan Leanderson T. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. *Lupus*.2016;0,1—11
- 50 Massardo L, Martínez ME, Pérez R, Ramírez V, Foradori A, dan González A. Capacity to predict a recurrence of lupus erythematosus using double-stranded anti-DNA antibodies and Farr technique. *Revista Medica de Chile*. 1999;127(4):411—20.
- 51 Saigal R, Goyal LK, Agrawal A, Mehta A, Mittal P, dan Yadav RN. Anti-nucleosome Antibodies in Patients with Systemic Lupus Erythematosus : Potential Utility as a Diagnostic Tool and Disease Activity

Marker and its Comparison with Anti-dsDNA Antibody. J Assoc Physicians India. 2013;61:372–7.

